COMMUNIQUÉS West-GlobeNewswire

Codexis Reports Second Quarter 2025 Financial Results
13/08/2025
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM [...]
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
13/08/2025
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI [...]
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
13/08/2025
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or [...]
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL [...]
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
13/08/2025
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line [...]
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of [...]
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
13/08/2025
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA [...]
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
13/08/2025
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 [...]
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
13/08/2025
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets [...]
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
13/08/2025
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets [...]
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
13/08/2025
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM- [...]
Aptose Reports Second Quarter 2025 Results
13/08/2025
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee ( CSRC) [...]
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
13/08/2025
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy ( [...]
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary [...]
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
13/08/2025
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is [...]
rYojbaba Co., Ltd. Announces Pricing of $5 Million Initial Public Offering of Japanese Common Shares and Listing on Nasdaq
13/08/2025
FUKUOKA, Japan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the pricing of its initial public offering of [...]
Corza Medical ouvre un laboratoire d’innovation pour les textiles biomédicaux afin d’accélérer le développement de produits FEO
13/08/2025
TAUNTON, Royaume-Uni, 13 août 2025 (GLOBE NEWSWIRE) -- Corza Medical, l’un des principaux fabricants mondiaux de technologies chirurgicales et de composants de dispositifs médicaux, a annoncé aujourd’hui l’ouverture de [...]
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs [...]

Pages